Bio-Amd Inc (BIAD) 0.2180 $BIAD Bio-AMD, Inc.;
Post# of 273322
Posted On: 04/12/2015 8:36:12 AM
Bio-Amd Inc (BIAD) 0.2180 $BIAD
Bio-AMD, Inc.; General Update & MIDS Plans
ACCESSWIRE - Tue Mar 31, 7:31AM CDT
LONDON, ENGLAND / ACCESSWIRE / March 31, 2015 / Bio-AMD, Inc. (OTCQB:BIAD) and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company"
provides an update on progress and the Company's plans for 2015. More information is available in the Company's 10K annual filing dated March 30, 2015.
Japanese Healthcare Giant Invests In A Point-Of-Care Coagulation Diagnostic System
Edward Vranic, CFA - at Seeking Alpha - Tue Mar 03, 7:55AM CST
Bio-AMD, Inc. Agreement with Sysmex & General Update
ACCESSWIRE - Tue Jan 27, 7:46AM CST
LONDON, ENGLAND / ACCESSWIRE / January 27, 2015 / Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company" (OTCQB: BIAD) provides an update on the Company's plans for 2015.
Bio-AMD, Inc.; Agreement with Sysmex and General Update
eTeligis - Tue Jan 27, 7:30AM CST
LONDON, United Kingdom, via ETELIGIS INC., 01/27/2015 - - Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company" (OTCQB: BIAD) provides an update on the Company's plans for 2015.
Bio-AMD, Inc., Innovate UK Offer of Funding Assistance
ACCESSWIRE - Wed Nov 19, 8:16AM CST
LONDON, ENGLAND / ACCESSWIRE / November 19, 2014 / Bio-AMD, Inc. and Bio AMD Limited, our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company" (OTCQB: BIAD) is pleased to announce that it has received an offer of a funding award assistance from Innovate UK, the UK's innovation agency, for a Proof of Market report covering the Company's Magnetic Immunoassay Detection System ("MIDS".
Bio-AMD, Inc.; Develops Multi-Reagent Microfluidic Test Strip
ACCESSWIRE - Tue Oct 07, 8:46AM CDT
LONDON, ENGLAND / ACCESSWIRE / October 7, 2014 / Bio-AMD, Inc. and Bio AMD Limited, our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company" (OTCQB: BIAD), is pleased to announce that it has successfully carried out internal testing on what it believes to be a novel microfluidic test strip capable of automated, multiple reagent immunoassay testing at the Point of Care ("POC".
Bio-AMD, Inc.; General Update & MIDS Plans
ACCESSWIRE - Tue Mar 31, 7:31AM CDT
LONDON, ENGLAND / ACCESSWIRE / March 31, 2015 / Bio-AMD, Inc. (OTCQB:BIAD) and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company"
provides an update on progress and the Company's plans for 2015. More information is available in the Company's 10K annual filing dated March 30, 2015. Japanese Healthcare Giant Invests In A Point-Of-Care Coagulation Diagnostic System
Edward Vranic, CFA - at Seeking Alpha - Tue Mar 03, 7:55AM CST
Bio-AMD, Inc. Agreement with Sysmex & General Update
ACCESSWIRE - Tue Jan 27, 7:46AM CST
LONDON, ENGLAND / ACCESSWIRE / January 27, 2015 / Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company"
(OTCQB: BIAD) provides an update on the Company's plans for 2015. Bio-AMD, Inc.; Agreement with Sysmex and General Update
eTeligis - Tue Jan 27, 7:30AM CST
LONDON, United Kingdom, via ETELIGIS INC., 01/27/2015 - - Bio-AMD, Inc. and Bio Alternative Medical Devices Ltd., our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company"
(OTCQB: BIAD) provides an update on the Company's plans for 2015. Bio-AMD, Inc., Innovate UK Offer of Funding Assistance
ACCESSWIRE - Wed Nov 19, 8:16AM CST
LONDON, ENGLAND / ACCESSWIRE / November 19, 2014 / Bio-AMD, Inc. and Bio AMD Limited, our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company"
(OTCQB: BIAD) is pleased to announce that it has received an offer of a funding award assistance from Innovate UK, the UK's innovation agency, for a Proof of Market report covering the Company's Magnetic Immunoassay Detection System ("MIDS". Bio-AMD, Inc.; Develops Multi-Reagent Microfluidic Test Strip
ACCESSWIRE - Tue Oct 07, 8:46AM CDT
LONDON, ENGLAND / ACCESSWIRE / October 7, 2014 / Bio-AMD, Inc. and Bio AMD Limited, our majority owned medical devices subsidiary (together "Bio-AMD", "We" or the "Company"
(OTCQB: BIAD), is pleased to announce that it has successfully carried out internal testing on what it believes to be a novel microfluidic test strip capable of automated, multiple reagent immunoassay testing at the Point of Care ("POC". 
(0)
(0)